• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Celsion Corporation

    8/11/23 4:06:12 PM ET
    $CLSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSN alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on August 11, 2023

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    IMUNON, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   52-1256615

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    997 Lenox Drive, Suite 100

    Lawrenceville, NJ

      08648

    (Address of principal executive offices)

     

    (Zip Code)

     

    IMUNON, INC. 2018 Stock Incentive Plan

    (Full title of the plan)

     

    Jeffrey W. Church

    Executive Vice President, Chief Financial Officer and Corporate Secretary

    997 Lenox Drive, Suite 100

    Lawrenceville, NJ 08648

    (609) 896-9100

    (Name, address and telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registration Statement shall become effective upon filing in accordance with Rule 462 under the Securities Act.

     

     

     


     

     

     

    EXPLANATORY NOTE

     

    The shareholders of Imunon, Inc. (the “Registrant”) approved an amendment to the Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 14, 2023 (the “Amended Plan”) on June 14, 2023 to increase the number of shares of the Company’s common stock, par value $0.01 (the “Common Stock”) that are available for issuance thereunder by 1,030,000 shares. This Registration Statement on Form S-8 is being filed by the Registrant for the purpose of registering an additional 1,030,000 shares of Common Stock, in accordance with the Amended Plan. Pursuant to Instruction E of Form S-8, the contents of the (i) the Form S-8 Registration Statement (File No. 333-266882) filed with the Securities and Exchange Commission (the “Commission”) on August 15, 2022, (ii) the Form S-8 Registration Statement (File No. 333-240275) filed with the Commission on July 31, 2020, (iii) the Form S-8 Registration Statement (File No. 333-233344) filed with the Commission on August 16, 2019, and (iv) the Form S-8 Registration Statement (File No. 333-225045) filed with the Commission on May 18, 2018 are incorporated by reference herein.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

     

      1) The Registrant’s annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 30, 2023;
      2) The Registrant’s quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the Commission on May 11, 2023;
      3) The Registrant’s quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2023, filed with the Commission on August 10, 2023;
      4) The Registrant’s current reports on Form 8-K and related amendments, filed with the Commission on January 3, 2023, February 10, 2023, March 24, 2023, June 14, 2023 and June 15, 2023;
      5) The portions of the Registrant’s definitive proxy statement on Schedule 14A filed with the Commission on April 28, 2023 that are deemed “filed” with the Commission under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and
      6)

    Description of Securities of the Registrant, incorporated herein by reference to Exhibit 4.5 to the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2019.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”). Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any current report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit
    No.
      Description
         
    4.1   Restated Certificate of Incorporation, dated March 22, 2023, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on March 24, 2023.
         
    4.2   Amended and Restated By-laws, effective on September 19, 2022, incorporated herein by reference to Exhibit 3.3 to the Current Report on Form 8-K of the Registrant, filed with the Commission on September 19, 2022.
         
    4.3   Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 14, 2023, incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on June 15, 2023.
         
    5.1*   Opinion of Baker & McKenzie LLP.
         
    23.1*   Consent of WithumSmith+Brown, PC.
         
    23.2*   Consent of Baker & McKenzie LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (set forth on the signature page of this Registration Statement).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lawrenceville, State of New Jersey on August 11, 2023.

     

      IMUNON, INC.
         
      By  /s/ Dr. Corinne Le Goff
        Corinne Le Goff
        President and Chief Executive Officer

     

    POWER OF ATTORNEY AND ADDITIONAL SIGNATURES

     

    Each person whose signature appears below constitutes and appoints Corinne Le Goff as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Dr. Corinne Le Goff   President, Chief Executive Officer and Director   August 11, 2023
    Corinne Le Goff, Pharm. D., MBA   (Principal Executive Officer)    
             
    /s/ Jeffrey W. Church   Executive Vice President, Chief Financial Officer and Corporate Secretary   August 11, 2023
    Jeffrey W. Church   (Principal Financial Officer)    
             
     /s/ Kimberly Bragg   VP of Finance, Corporate Controller   August 11, 2023
    Kimberly Bragg   (Principal of Accounting Officer)    
             

    /s/ Michael H. Tardugno

     

    Executive Chairman of the Board of Directors

      August 11, 2023
    Michael H. Tardugno        
             
    /s/ Frederick J. Fritz   Director   August 11, 2023
    Frederick J. Fritz        
             
    /s/ James E. Dentzer   Director   August 11, 2023
    James E. Dentzer        
             
    /s/ Donald Braun, Ph.D.   Director   August 11, 2023
    Donald Braun, Ph.D.        
             
    /s/ Christine A. Pellizzari   Director   August 11, 2023
    Christine A. Pellizzari        
             
    /s/ Dr. Stacy R. Lindborg   Director   August 11, 2023
    Dr. Stacy R. Lindborg        

     

     

    Get the next $CLSN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hazard Sebastien was granted 20,000 shares (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:07:24 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hazard Sebastien claimed no ownership of stock in the company (SEC Form 3)

      3 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:05:23 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Braun Donald P

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/21/23 4:42:32 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/14/22 3:17:01 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/11/22 6:10:51 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Celsion CORP (0000749647) (Subject)

      2/1/21 3:15:37 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CLSN
    Financials

    Live finance-specific insights

    See more

    $CLSN
    SEC Filings

    See more
    • Celsion Corporation Announces Company Name Change to Imunon, Inc.

      New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022. The Company has filed an amendmen

      9/19/22 4:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

      110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with S

      9/15/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

      LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person participation at the Lotte New York Palace Hotel. Dr. Le Goff is also available for in-person meetings at the conference. About Celsion Corporation Celsion is a fully integrated, clinical-stage biotechnol

      9/12/22 6:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

      LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologie

      8/8/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

      LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      5/9/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

      LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      3/24/22 9:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1/A filed by Celsion Corporation (Amendment)

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      2/9/24 4:09:15 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Imunon, Inc. (0000749647) (Filer)

      12/29/23 4:30:19 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Celsion Corporation

      S-1 - Imunon, Inc. (0000749647) (Filer)

      12/20/23 5:15:25 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

      Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company's Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will continue to serve as Executive Chairman of Celsion's Board of Directors. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas i

      7/19/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Science 37® Appoints Christine Pellizzari as Chief Legal Officer

      With this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced that Christine Pellizzari has joined the senior executive team as Chief Legal Officer. In this role, Ms. Pellizzari will use her nearly 30 years of legal expertise to manage the legal and quality functions to help advance Science 37's mission to enable universal access to clinical research for patients and providers, anywhere. This press release features multimedia. View the full release here: https://www.business

      9/1/21 7:55:00 AM ET
      $CLSN
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Appoints Christine A. Pellizzari to its Board of Directors

      Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021. Ms. Pellizzari is Chief Legal Officer of Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases and brings to Celsion more than 20 years of leadership i

      6/9/21 8:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care